Business Wire

Celonis Accelerates its Process Mining and Execution Management Leadership in India

29.11.2021 11:53:00 EET | Business Wire | Press release

Share

Celonis, the global leader in execution management, today announced that it will expand its process mining and execution management operations into India. Celonis believes the opportunity for customers, global system integrators (GSIs), business process outsourcing (BPO) providers, consultants, and academics is as big as the shift from on-prem to cloud.

As part of its execution management initiative in India, Celonis has committed to investing over $100 million dollars into the Indian process industry and expects to create more than 1,000 jobs. The expansion into India enables the world’s leading business process professionals and experts to unlock billions in new process and execution value for both their customers and within their own companies. The Celonis execution management initiative was launched at a multi-day press conference and partner ecosystem event in Bangalore, India.

The opportunity for process mining and execution management in India is immense. To provide context, Everest Group reports that the India BPO market for financial services alone has the potential to grow from $18 billion to $250 billion and currently represents nearly half of the world’s global outsourcing market. Furthermore, IDC estimates that the Indian IT & Business Services1 market will grow from $7 billion to $20 billion by 2025.

“Process mining should be at the core of digital transformation efforts and can play a critical role in helping to achieve greater scale, agility, and business value realization,” said Amardeep Modi, Vice President, Everest Group. “Celonis partners and customers in India will likely benefit greatly by having this new hub to assist, train, and promote best practices for the region. It would also help tap into India’s large talent base to fulfil the fast-growing demand for process mining skills globally.”

“India is undeniably a top global talent hub, and an IT and operations stronghold for Global 2000 enterprises,” said Reetika Fleming, Research Leader at HFS Research. “With this investment, Celonis is taking its technology right where it is needed. This will make it much easier for service providers to develop data-proficient workforces and presents an exciting opportunity for Indian students and consultants to work with process intelligence technologies.”

The Celonis India execution management initiative is designed around three strategic pillars that will enable the entire India process industry, and eventually every company across all sectors, to immediately adopt the most state of the art technologies into their core operations:

  • Execution Management Without Limits: The first pillar of this initiative is the rollout of the Celonis Execution Management Without Limits and the Celonis for BPO programs. These industry-first programs allow unlimited access to Celonis process mining and execution management technologies to any BPO, GSI and consulting professional.
  • Celonis Academy: The second pillar of this initiative is to provide free training and access to the best-in-class methods, processes, and programs for process mining and execution management to the entire India process consulting industry. Celonis plans to initially train more than 100,000 consultants, students and academics in India. This program is part of a global initiative where Celonis will train more than 1 million experts on process mining and execution management.
  • Celonis Center of Excellence: The third pillar is the new Celonis Center of Excellence (CoE) which will be the one-stop shop for customers, partners and service providers in India. The CoE combines partner enablement support, professional services and value advisory for customers, a dedicated product engineering team, and a customer support team to provide around-the-clock expertise and innovation.

“Every significant process innovation wave, from client server, to the internet, to the cloud has gone through the heart of the India business process industry,” said Bastian Nominacher, co-CEO and co-founder of Celonis. “Celonis is honored to help drive the next generational shift in process modernization in India by embedding our state-of-the-art process mining and execution management technologies into the world’s leading BPO, GCC, GSI and consulting firms.”

The Celonis partner ecosystem already includes many of the top tier consultancies, business process outsourcing (BPO) providers and consulting firms around the world, such as Accenture, Cognizant, Deloitte, EY, Firstsource, HCL, IBM, Infosys, KPMG, PWC, TCS, Tech Mahindra, Wipro, WNS and more. All of whom use the Celonis EMS to power digital and process transformation initiatives - for themselves and their clients.

“Celonis has removed all barriers for the entire India process ecosystem to put data to work and arm companies and organizations in every industry with our Execution Management System - which our customers call the ‘process brain’ for their businesses,” said Malhar Kamdar, Chief Customer Officer for Celonis and Executive leader for India. “Celonis has fully opened our platform with the goal of unlocking billions of value for users, enterprises and society. We are thrilled to bring the power of data execution to all our customers and partners in India.”

"Celonis is a key partner for Bosch worldwide, as we work together to bring our software offerings and process analytics to the next level, required to foster our ambition to become a data-driven, leading AIoT company,” said Jens Bockholt, VP Regional Manager at Bosch. “We are delighted that Celonis is continuing their global expansion with a new Center of Excellence in India and we look forward to further collaborating and leveraging Celonis to better serve our customers. We believe this will be mutually beneficial for both Celonis and the growing Indian marketplace.”

At their 2021 World Tour, Celonis announced a series of investments across each of the three key imperatives of the Celonis Execution Management System (EMS) - data, intelligence and action. This included the acquisition of real-time streaming data technology Lenses.io; the launch of the Celonis Execution Graph, that connects events from different processes across the company to identify bottlenecks; and a planned market defining partnership with ServiceNow.

“India’s market and talent base represents an unparalleled opportunity to capitalize on the global adoption of process mining and execution management at a massive scale,” said Anitha Scaria George, VP and Head of Celonis India. “As with every movement, there are companies who trailblaze and leapfrog the competition, and those who find themselves at the back of the parade. Celonis will train the next generation of execution management leaders to apply data, intelligence, and action to every process, in every business, in every industry.”

About Celonis

Celonis helps organizations to execute on their data. Powered by its market-leading process mining core, the Celonis Execution Management System provides a set of applications, a developer studio and platform capabilities for business executives and users to eliminate billions in corporate inefficiencies, provide better customer experience and reduce carbon emissions. Celonis has thousands of global customers and is headquartered in Munich, Germany and New York City, USA with 16 offices worldwide.

© 2021 Celonis SE. All rights reserved. Celonis and the Celonis “droplet” logo are trademarks or registered trademarks of Celonis SE in Germany and other jurisdictions. All other product and company names are trademarks or registered trademarks of their respective owners. 


1 tps://www.idc.com/getdoc.jsp?containerId=prAP48371321

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Isabell Horvath
VP Communications
i.horvath@celonis.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye